Consolidated financial statements

CONSOLIDATED BALANCE SHEET

Asset items	31/12/2022	31/12/2021
10. Cash and cash equivalents	13,130,815	29,153,316
20. Financial assets at fair value through profit and loss	8,935,495	6,337,110
a) financial assets held for trading	4,508,497	4,538,625
c) other financial assets mandatorily measured at fair value	4,426,998	1,798,485
30. Financial assets measured at fair value through other comprehensive income	12,826,691	10,675,079
40. Financial assets at amortised cost	139,139,766	140,448,388
a) loans to banks	5,492,238	12,773,990
b) loans to customers	133,647,528	127,674,398
50. Hedging derivatives	1,717,211	127,076
60. Fair value change of financial assets in macro fair value hedge portfolios (+/-)	(488,403)	2,875
70. Interests in associates and joint ventures	1,453,955	1,794,116
80. Technical reserves of reinsurers	3,087	-
90. Property, plant and equipment	3,034,689	3,278,245
100. Intangible assets	1,286,734	1,213,722
of which:		
- goodwill	56,709	54,858
110. Tax assets	4,622,827	4,540,229
a) current	265,552	246,601
b) deferred	4,357,275	4,293,628
120. Non-current assets and disposal groups held for sale	214,737	229,971
130. Other assets	3,808,291	2,689,089
Total assets	189,685,895	200,489,216

Liabilities and shareholders' equity items	31/12/2022	31/12/2021
10. Financial liabilities at amortised cost	153,874,094	166,561,146
a) due to banks	32,636,506	45,691,578
b) due to customers	108,307,067	107,788,219
c) debt securities in issue	12,930,521	13,081,349
20. Financial liabilities held for trading	10,181,692	14,132,931
30. Financial liabilities designated at fair value	3,938,518	1,405,190
40. Hedging derivatives	948,424	227,972
50. Fair value change of financial liabilities in macro fair value hedge portfolios (+/-)	(1,173,078)	(47,812)
60. Tax liabilities	279,983	302,816
a) current	1,610	8,894
b) deferred	278,373	293,922
70. Liabilities associated with assets classified as held for sale	31 <i>,7</i> 31	-
80. Other liabilities	3,430,984	3,613,968
90. Provisions for employee severance pay	258,457	320,303
100. Provisions for risks and charges	730,395	876,643
a) commitments and guarantees given	144,164	131,108
b) post-employment benefits and similar obligations	99,330	124,879
c) other provisions	486,901	620,656
110. Technical reserves	4,414,424	-
120. Valuation reserves	(624,011)	341,360
140. Equity instruments	1,389,794	1,092,832
150. Reserves	4,219,445	3,999,850
170. Share capital	7,100,000	7,100,000
180. Own shares (-)	(18,266)	(8,159)
190. Non-controlling interests (+/-)	720	1,108
200. Profit (loss) for the year (+/-)	702,589	569,068
Total liabilities and shareholders' equity	189,685,895	200,489,216

CONSOLIDATED INCOME STATEMENT

Item	5	2022	2021
10.	Interest and similar income	2,937,053	2,425,188
	of which: interest income using the effective interest method	2,656,868	2,137,845
20.	Interest and similar expense	(595,587)	(409,048)
30.	Net interest income	2,341,466	2,016,140
40.	Fee and commission income	1,998,389	2,018,601
50.	Fee and commission expense	(143,896)	(117,906)
	Net fee and commission income	1,854,493	1,900,695
_ 70.	Dividends and similar income	60,840	53,718
	Net trading income	174,105	79,523
	Fair value gains/losses on hedging derivatives	1,402	(848)
100.	Gains (losses) on disposal or repurchase of:	(165,927)	(129,080)
	a) financial assets at amortised cost	(60,948)	(145,262)
	b) financial assets measured at fair value through other comprehensive income	(101,636)	16,256
	c) financial liabilities	(3,343)	(74)
110.	Net gains (losses) from other financial assets and liabilities measured at fair value through profit and loss	(9,146)	16,342
	a) financial assets and liabilities designated at fair value	163,348	7,894
	b) other financial assets mandatorily measured at fair value	(172,494)	8,448
120.	Operating income	4,257,233	3,936,490
130.	Net credit impairment losses/recoveries relating to:	(482,702)	(630,954)
	a) financial assets at amortised cost	(480,574)	(629,997)
	b) financial assets measured at fair value through other comprehensive income	(2,128)	(957)
140.	Gains (losses) from contractual modification without derecognition	1,713	(8,521)
150.	Net income from financial activities	3,776,244	3,297,015
	Net premiums	359,803	
	Balance of other income/expenses from insurance activities	(357,484)	-
	Net income from financial and insurance activities	3,778,563	3,297,015
190.	Administrative expenses:	(2,758,642)	(2,771,573)
	a) personnel expenses	(1,609,881)	(1,670,739)
	b) other administrative expenses	(1,148,761)	(1,100,834)
200.	Net provisions for risks and charges	(57,214)	(26,039)
	a) commitments and guarantees given	(14,407)	(5,254)
	b) other net provisions	(42,807)	(20,785)
	Depreciation and impairment losses on property, plant and equipment	(183,093)	(165,828)
	Amortisation and impairment losses on intangible assets	(135,102)	(114,457)
	Other operating expenses/income	345,930	363,082
	Operating expenses	(2,788,121)	(2,714,815)
	Gains (losses) of associates and joint ventures	146,781	213,314
	Fair value gains (losses) on property, plant and equipment and intangible assets	(108,347)	(141,633)
	Value adjustments to goodwill	(8,132)	-
	Gains (losses) on disposal of investments	2,258	(142)
	Profit (loss) before tax from continuing operations	1,023,002	653,739
	Taxation charge related to profit or loss from continuing operations	(321,199)	(84,955)
	Profit (loss) after tax from continuing operations	701,803	568,784
	Profit (loss) for the year	701,803	568,784
	Profit (loss) for the year attributable to non-controlling interests	786	284
350.	Parent Company's profit (loss) for the year	702,589	569,068
	Basic EPS (euro)	0.46	0.38
	Diluted EPS (euro)	0.46	0.38

STATEMENT OF CONSOLIDATED COMPREHENSIVE INCOME

Items	31/12/2022	31/12/2021
10. Profit (loss) for the year	701,803	568,784
Other comprehensive income after tax without reclassification to the		
income statement	2,018	139,815
20. Equity instruments designated at fair value through other comprehensive income	(35,428)	14,591
30. Financial liabilities designated at fair value through profit and loss (changes to its own credit risk)	(8,478)	2,131
50. Property, plant and equipment	4,883	128,784
70. Defined benefit plans	40,378	(5,517)
90. Share of valuation reserves related to interests in associates and joint ventures carried		
at equity	663	(174)
Other comprehensive income after tax with reclassification to the income		
statement	(952,330)	(108,790)
100. Foreign investment hedges	(872)	(802)
110. Exchange rate differences	2,371	2,138
120. Cash flow hedges	(11,239)	(12,129)
140. Financial assets (other than equity instruments) measured at fair value through other		
comprehensive income	(739,300)	(86,744)
160. Share of valuation reserves related to interests in associates and joint ventures carried		
at equity	(203,290)	(11,253)
170. Total other comprehensive income after tax	(950,312)	31,025
180. Comprehensive income (Items 10+170)	(248,509)	599,809
190. Consolidated comprehensive income attributable to non-controlling interests	(786)	(284)
200. Consolidated comprehensive income attributable to the Parent Company	(247,723)	600,093

STATEMENT OF CHANGES IN CONSOLIDATED SHAREHOLDERS' EQUITY

				;	,				ક	Changes in the year	ħ						
31 December 2022	Balance as at	Changes in	Balance as at	Allocation of profit from previous year					Operations	Operations on shareholders' equity	s' equity			Comprehensiv	Shareholders'	Group shareholders'	Non- controlling
	31/12/2021	balances	01/01/2022	Reserves	Dividends and other allocations	Changes in reserves	Issue of Pu	Purchase Ex of own di shares	Extraordinary distribution of dividends	Changes in equity instruments	Derivatives on own shares	Stock options	Changes in equity interests		31/12/2022	equity as at 31/12/2022	interests as at 31/12/2022
Share capital:	7,100,736		7,100,736				•						(2)		7,100,731	7,100,000	731
a) ordinary shares	7,100,736		7,100,736										(5)		7,100,731	7,100,000	731
b) other shares																	
Share premium reserve	•					•	•						•		•	•	•
Reserves:	4,000,506		4,000,506	280,448		(54,799)	(5,935)		٠			•			4,220,220	4,219,445	775
a) retained earnings	3,670,845	٠	3,670,845	280,448		(69,580)	(5,935)						•		3,875,778	3,875,001	777
b) other	329,661	,	329,661	•		14,781	,					,			344,442	344,444	(2)
Valuation reserves	341,360	•	341,360			(15,059)							•	(950,312)	(624,011)	(624,011)	•
Equity instruments	1,092,832		1,092,832							296,962					1,389,794	1,389,794	•
Own shares	(8,159)		(8,159)				5,909 (16,016)	(16,016)							(18,266)	(18,266)	•
Profit (loss) for the year	568,784		568,784	(280,448)	(288,336)									701,803	701,803	702,589	(786)
Shareholders' equity	13,096,059		13,096,059	•	(288,336)	(858'69)	(26)	(26) (16,016)	٠	296,962	٠	•	(5)	(248,509)	12,770,271	12,769,551	720
- of the Group	13,094,951	•	13,094,951	•	(288,336)	(70,261)	(26)	(26) (16,016)		296,962	•	٠	•	(247,723)	12,769,551		
- of non-controlling interests	1,108	•	1,108	•		403				•	•	•	(3)	(786)	720		

				Allocation	Allocation of profit from				Char	Changes in the year	ī						į
31 December 2021	Balance as at	Changes in opening	Balance as at	previo	previous year				Operations	Operations on shareholders' equity	rs' equity		Compre				controlling
	31/12/2020	balances	1707/10/1	Reserves	Dividends and other allocations	reserves	Issue of new shares	Purchase of own shares	Extraordinary distribution of dividends i	Changes in equity instruments	Derivatives on Stock options own shares	Changes in ons equity interests	in e income ds at 31/12/2021	1e ds 31/12/2021 2021		equity as ar intra 31/12/2021 31	31/12/2021
Share capital:	7,101,310	·	- 7,101,310			•		•				ت	(574)	01,7	7,100,736 7	7,100,000	736
a) ordinary shares	7,101,310		016,101,310										(574)	7,10	7,100,736	7,100,000	736
b) other shares																	
Share premium reserve	•	·				•		•									•
Reserves:	4,117,332		- 4,117,332	16,632		(38,792)	(4,194)		(90,544)		•		72	4,00	4,000,506 3	3,999,850	929
a) retained earnings	3,796,621		3,796,621	16,632		(47,742)	(4,194)		(90,544)				72	3,67	3,670,845	3,670,187	859
b) other	320,711		320,711			8,950								37	329,661	329,663	(2)
Valuation reserves	310,412		- 310,412			(77)								31,025 34	341,360	341,360	•
Equity instruments	695,417		. 695,417							397,415				1,09	1,092,832	1,092,832	•
Own shares	(14,002)	•	. (14,002)			•	5,843	•						3)	(8,159)	(8,159)	•
Profit (loss) for the year	16,632		- 16,632	(16,632)									26	568,784 56	568,784	269,068	(284)
Shareholders' equity	12,227,101		- 12,227,101			(38,869)	1,649		(90,544)	397,415		-	(502) 59	599,809 13,09	13,096,059 13	13,094,951	1,108
- of the Group	12,225,207	•	. 12,225,207		•	(38,869)	1,649	•	(90,544)	397,415	•			600,093 13,09	13,094,951		
- of non-controlling interests	1,894	•	1,894			•		•				ت ا	(502)	(284)	1,108		

CONSOLIDATED CASH FLOW STATEMENT

Indirect method

Α. (Operating activities	31/12/2022	31/12/2021
	1. Cash flow from operations	1,763,018	1,270,260
- F	orofit (loss) for the year (+/-)	<i>7</i> 01,803	568,784
	gains/losses on financial assets held for trading and on other financial assets/liabilities at		
	fair value through profit and loss (-/+)	(14,535)	(111,965)
	capital gains/losses on hedging derivatives (-/+)	(1,402)	848
	net credit impairment losses/recoveries (-/+)	480,989	639,475
	net impairment losses/recoveries on property, plant and equipment and intangible assets (+/-)	326,327	280,285
	net provisions for risks and charges and other costs/revenues (+/-)	63,260	28,229
	net premiums not collected (-)	(153)	20,227
	other insurance income/expenses not collected (-/+)	57,287	
	taxes, duties and tax credits not settled (+/-)	306,139	77,587
	net impairment losses/recoveries on discontinued operations net of taxes (-/+)	300,137	77,307
	other adjustments (+/-)	(156,697)	(212,983)
	2. Cash flow from/used in financial assets	(6,079,114)	2,433,061
	financial assets held for trading	40,287	2,762,800
	financial assets designated at fair value	40,267	2,702,800
	other financial assets mandatorily measured at fair value	12 702 0701	41.470
	<u>, </u>	(2,793,070)	41,670
	financial assets measured at fair value through other comprehensive income	(2,153,740)	34,760
		829,761	162,417
	other assets	(2,002,352)	(568,586)
	3. Cash flow from/used in financial liabilities	(11,359,632)	15,977,948
	financial liabilities at amortised cost	(12,490,168)	15,962,095
	financial liabilities held for trading	(6,336,795)	2,457,926
	financial liabilities designated at fair value	1,246,802	469,112
	other liabilities	6,220,529	(2,911,185)
	Net cash flow from/used in operating activities	(15,675,728)	19,681,269
	Investing activities		
	1. Cash flow from:	76,839	18,036
	sales of interests in associates and joint ventures	75,000	314
	dividends collected on interests in associates and joint ventures	-	-
	sales of property, plant and equipment	1,839	17,722
	sales of intangible assets	-	-
	sales of subsidiaries and business segments	-	
	2. Cash flow used in:	(327,275)	(198,527)
	purchases of interests in associates and joint ventures	(700)	-
	purchases of property, plant and equipment	(122,290)	(92,323)
	purchases of intangible assets	(204,285)	(106,204)
	purchases of subsidiaries and business segments	-	-
ı	Net cash flow from/used in investing activities	(250,436)	(180,491)
C. I	Financing activities		
- i	issues/purchases of own shares	(16,016)	-
	issues/purchases of equity instruments	208,015	332,395
- (dividend distribution and other allocations	(288,336)	(90,544)
- t	hird-party sales/purchases	-	-
I	Net cash flow from/used in financing activities	(96,337)	241,851
	Net cash flow from/used during the year	(16,022,501)	19,742,629

	Reconciliation	31/12/2022	31/12/2021
-	Cash and cash equivalents at the beginning of the year	29,153,316	9,410,687
-	Net cash flow from/used during the year	(16,022,501)	19,742,629
-	Cash and cash equivalents: foreign exchange effect	-	-
	Cash and cash equivalents at the end of the year	13,130,815	29,153,316

Below is the information required under IAS 7, paragraph 44, A and B.

			Non-m	onetary chang	jes	
(thousands of euro)	31/12/2021	Cash flows	Business combinations/ loss of control of companies	Fair value changes	Other	31/12/2022
Liabilities deriving from loan activities (items						
10, 20 and 30 in the liabilities)	182,099,267	(17,580,161)	1,104,863	2,166,059	204,276	167,994,304